Wellington Management Group LLP Purchases 11,763 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Wellington Management Group LLP increased its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 8.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 147,499 shares of the biotechnology company’s stock after buying an additional 11,763 shares during the quarter. Wellington Management Group LLP owned 0.26% of Astria Therapeutics worth $1,624,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Quest Partners LLC boosted its stake in shares of Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares during the last quarter. PDT Partners LLC purchased a new position in Astria Therapeutics during the third quarter valued at $140,000. SG Americas Securities LLC bought a new position in shares of Astria Therapeutics during the 3rd quarter valued at approximately $155,000. Hsbc Holdings PLC bought a new position in shares of Astria Therapeutics in the second quarter worth approximately $171,000. Finally, Intech Investment Management LLC bought a new position in Astria Therapeutics in the 3rd quarter worth $228,000. 98.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Oppenheimer increased their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Trading Down 2.0 %

Shares of ATXS stock opened at $9.36 on Thursday. The stock’s 50-day moving average price is $10.72 and its 200-day moving average price is $10.70. Astria Therapeutics, Inc. has a 12-month low of $5.88 and a 12-month high of $16.90. The stock has a market capitalization of $528.22 million, a price-to-earnings ratio of -4.48 and a beta of 0.67.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.